Last updated July 22, 2026
Key finding
At 6 months the difference was significant (p = 0.046).
This study evaluated the impact of metronidazole as an adjunct to scaling and root planing on insulin resistance in type 2 diabetes patients with periodontitis, finding significant changes in HOMA-IR at 6 months.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the impact of metronidazole as an adjunct to scaling and root planing on insulin resistance in type 2 diabetes patients with periodontitis, finding significant changes in HOMA-IR at 6 months.
This study highlights the potential role of periodontal treatment in managing insulin resistance among type 2 diabetes patients. Effective management of periodontitis may not only improve oral health but also contribute to better metabolic control, which is crucial for diabetes management.
The study design was non-randomized, which may introduce bias. Sample size and demographic details were not specified. Results may not be generalizable to all populations with diabetes.
Published in
Publication details and source links for this paper.
Ambrina Q, Zeba H, Hina Q, Waqas AF, Andreas B, Felix K. Effects of Metronidazole as an Adjunct to Scaling Root Planing on Insulin Resistance in Type 2 Diabetes Mellitus Patients with Periodontitis. Antibiotics. 2021;10(11):1400. doi:10.3390/antibiotics10111400
At 3 months, no significant difference in HOMA-IR was observed between groups (p = 0.05).
At 6 months, the group receiving metronidazole showed a significant decrease in HOMA-IR (p = 0.046).
Overall, the addition of metronidazole improved insulin resistance compared to the control group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Control Group Usual Activity, Scaling and root planing with metronidazole, Scaling and root planing without metronidazole and HOMA-IR measured at 3 months, Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months.
This study contributes evidence to
Primary intervention
Control Group Usual Activity
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
6
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Control Group Usual Activity → HOMA-IR measured at 3 months
Control Group Usual Activity → HOMA-IR measured at 3 months
Control Group Usual Activity → Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
Control Group Usual Activity → Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
Scaling and root planing with metronidazole → HOMA-IR measured at 3 months
Scaling and root planing with metronidazole → HOMA-IR measured at 3 months
Scaling and root planing with metronidazole → Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
Scaling and root planing with metronidazole → Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
Scaling and root planing without metronidazole → HOMA-IR measured at 3 months
Scaling and root planing without metronidazole → HOMA-IR measured at 3 months
Scaling and root planing without metronidazole → Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
Scaling and root planing without metronidazole → Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Control Group Usual Activity and HOMA-IR measured at 3 months, Control Group Usual Activity and Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months.
This study contributes to the evidence on the following intervention-outcome relationships.
Physical Activity
Physical Activity
Curated evidence collections and hubs this study is part of.
All studies on Control Group Usual Activity
Contributes to Control Group Usual Activity evidence base.
All studies measuring HOMA-IR measured at 3 months
Measures HOMA-IR measured at 3 months as a key outcome.
All studies measuring Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
Measures Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Scaling and root planing with metronidazole appears to improve Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Scaling and root planing without metronidazole appears to improve Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Control Group Usual Activity for HOMA-IR measured at 3 months.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HOMA-IR measured at 3 months
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Control Group Usual Activity for Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Homeostasis model assessment of insulin resistance (HOMA-IR) at 6 months
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
